Inspiration Healthcare Reports 24% Revenue Growth and Major US Contract in FY26 Trading Update

FY26 trading update: 24% revenue growth and a landmark US deal

Inspiration Healthcare Group has delivered a punchy FY26 trading update: revenue up 24.0% to £47.5 million, a strong H2, and a three-year purchasing agreement in the United States that could reshape the Group’s revenue mix. Adjusted EBITDA is expected to be in line with market consensus, while net debt has been cut by 39% to £5.1 million.

Management’s ‘Back to Basics’ strategy is showing through in better execution, improved cash discipline, and clearer business unit focus. The pipeline looks solid heading into FY27, with momentum particularly evident in SLE’s neonatal ventilation and Airon’s US opportunity.

Headline numbers at a glance

Metric	FY26/Period	Prior/Reference	Change/Notes
Group revenue (FY26)	£47.5 million	FY25: £38.3 million	+24.0%
H2 revenue	£23.5 million	H2 FY25: £21.3 million	+10.3% year-on-year
Adjusted EBITDA	In line	Consensus: £2.8 million	Sales mix effects cited
Revenue vs consensus	£47.5 million	Consensus: £44.1 million	Slightly ahead
Net debt (31 Jan 2026, excl. IFRS 16)	£5.1 million	31 Jan 2025: £8.3 million	-39%, driven by lower inventory and receivables

What’s driving growth: SLE rebound and Airon’s US traction

SLE’s international momentum returns

SLE, the Group’s neonatal ventilation leader, outperformed expectations in H2 after the Group refreshed its branding and sharpened go-to-market execution. With local distributor managers now in place in Southeast Asia and Latin America, SLE looks set to re-establish its international position. That matters because neonatal ventilation is a high-spec, defensible niche where strong brand and clinical trust translate into repeatable orders and long asset lifecycles.

The update suggests SLE’s H2 step-up was material to the Group’s overall beat on revenue consensus. The link between better operational execution and international growth is clear – a good sign for FY27 if the new regional structure beds in.

Airon’s three-year US purchasing agreement

Through Florida-based Airon, Inspiration Healthcare has signed a multi-year purchasing agreement with one of the largest US hospital networks. It includes an initial order for 150 Model A and Neo ventilators and accessories, immediately expanding the installed base and laying the groundwork for ongoing consumables and service revenue.

This is important on two fronts. First, it creates a high-quality, long-term revenue stream with a blue-chip counterparty. Second, it directly supports the Group’s aim to double Airon revenue within five years. The installed base effect – selling consumables and servicing over time – can lift gross margins and smooth cash flows versus lumpy capital equipment sales.

Profitability and cash: steady EBITDA, cleaner balance sheet

Adjusted EBITDA is expected to land in line with consensus at £2.8 million. Management points to sales mix effects – in plain English, the blend of products and regions sold can shift margins up or down. The key takeaway is that, despite strong top-line growth, profitability has not expanded beyond expectations this year.

Cash discipline stands out. Net debt (excluding IFRS 16 lease liabilities) fell 39% to £5.1 million thanks to significant reductions in inventory and receivables. That de-risks the story, reduces interest costs, and gives more room to invest in growth without stretching the balance sheet.

Strategy check: ‘Back to Basics’ and focused business units

The ‘Back to Basics’ plan is visible in how the Group is organised and what it is prioritising:

• SLE – global neonatal ventilation brand with renewed push in international markets.
• Inspiration Healthcare – medtech distribution channel for the UK and Ireland.
• Airon – global leader in pneumatic ventilation, now with a cornerstone US hospital network agreement.

The emphasis on Europe, plus growing recurring revenues from consumables and service, targets higher-quality revenue streams to complement capital equipment sales. If executed well, this blend should steadily improve gross margins and cash conversion over time.

Outlook for FY27: pipeline and momentum

Management flags “good sales momentum” into FY27 with a “solid pipeline of opportunities”. Combined with SLE’s international rebuild and Airon’s US contract, that sets a constructive tone for the new year. The raised installed base should help build annuity-style revenues from accessories, consumables, and servicing.

There’s no formal guidance here beyond the qualitative comments, and detailed divisional breakouts are not disclosed in this update. The full-year results will be the next key checkpoint for margin trajectory and cash flow detail.

Josh’s take: what looks good, and what to watch

Positives

• Revenue execution: £47.5 million, ahead of the £44.1 million consensus, shows demand strength and operational follow-through.
• Quality of growth: a multi-year US hospital deal at Airon adds visibility and recurring revenue potential.
• International rebuild: SLE’s H2 beat and new distributor managers in Southeast Asia and Latin America support sustainable growth.
• Balance sheet progress: net debt down 39% to £5.1 million via tighter working capital.

Watch-outs

• Margins flat to consensus: adjusted EBITDA “in line” implies sales outperformance did not translate into a bigger profit beat, likely due to sales mix.
• Execution is key: the strategy relies on distributor-led international growth and converting installed base into consumables and service – both require consistent delivery.
• Contract concentration: the US agreement is a clear positive, but long-term value will hinge on follow-on orders and the ramp in consumables and service revenue.

Key terms explained (quickly)

• Adjusted EBITDA – earnings before interest, tax, depreciation and amortisation, adjusted for specific items. A proxy for underlying operating profitability.
• Net debt (excl. IFRS 16) – borrowings minus cash, excluding lease liabilities accounted for under IFRS 16. A cleaner view of financial leverage.
• Sales mix effects – the margin impact from selling different products or selling into different regions or channels.
• Installed base and consumables – once equipment is placed, hospitals typically buy compatible disposables and services over time, creating recurring revenue.

Bottom line: momentum building with improving quality of earnings

This is a confident update from Inspiration Healthcare. Top-line growth of 24.0% to £47.5 million, a three-year US hospital network agreement, and a 39% cut in net debt make for a stronger platform into FY27. While EBITDA is only in line with consensus, the direction of travel – more recurring revenue, better international coverage, and tighter working capital – is encouraging.

If SLE maintains its H2 pace and Airon’s US partnership scales as planned, the mix should tilt toward higher-quality, stickier revenues. The next results will need to show that momentum converting into margin expansion and continued cash generation.